The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Biotechnology Act Europe Driving Innovation and Investment in Life Sciences
The Biotechnology Act Europe offers a once-in-a-generation chance to turn the continent’s world-class life sciences research into scalable commercial successes that remain in Europe rather than migrating elsewhere. By tackling regulatory fragmentation and sharpening investment signals, the legisl...
Rising Trends in Early-Onset Colorectal Cancer Burden
Early-onset colorectal cancer is rising sharply among adults under 50, even as overall colorectal cancer incidence and mortality have declined through improved prevention and treatment. Contemporary adults aged 30 to 40 now face higher risks at younger ages than their grandparents did, with the d...
FDA Importation Program Analysis on Colorado’s Prescription Drug Initiative
This FDA Importation Program Analysis confirms that Colorado has secured a two-year authorization to import eligible prescription drugs under its Section 804 Importation Program (SIP), demonstrating that significant cost savings for American consumers are achievable without compromising safety or...